{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:29:03Z","timestamp":1784658543185,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17fk0210104h0001"],"award-info":[{"award-number":["17fk0210104h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Meyers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Meyers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Meyers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bbrc.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T05:36:36Z","timestamp":1523597796000},"page":"152-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice"],"prefix":"10.1016","volume":"500","author":[{"given":"Yuji","family":"Teraoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-8287","authenticated-orcid":false,"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Abe-Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Naswa","family":"Makokha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chise","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.04.005_bib1","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2132::AID-CNCR6>3.0.CO;2-H","article-title":"Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis","volume":"85","author":"Chiaramonte","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2018.04.005_bib2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/jhep.2000.19288","article-title":"Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis","volume":"32","author":"Sagnelli","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2018.04.005_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2018.04.005_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01620-17","article-title":"In\u00a0vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2018.04.005_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In\u00a0vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2018.04.005_bib6","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection","author":"Kumada","year":"2017","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.bbrc.2018.04.005_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir\/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2018.04.005_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165339","article-title":"Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure","volume":"11","author":"Itakura","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.04.005_bib9","article-title":"Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in HCV infected patients receiving glecaprevir and pibrentasvir in Japan","volume":"62","author":"Krishnan","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2018.04.005_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142145","article-title":"Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice","volume":"10","author":"Tateno","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.04.005_bib11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1099\/jgv.0.000726","article-title":"Usefulness of humanized cDNA-uPA\/SCID mice for the study of hepatitis B virus and hepatitis C virus virology","volume":"98","author":"Uchida","year":"2017","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.bbrc.2018.04.005_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3851\/IMP3009","article-title":"Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice","volume":"21","author":"Kan","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bbrc.2018.04.005_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.virusres.2015.11.010","article-title":"Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice","volume":"213","author":"Uchida","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.bbrc.2018.04.005_bib14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1099\/vir.0.83658-0","article-title":"Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice","volume":"89","author":"Kimura","year":"2008","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.bbrc.2018.04.005_bib15","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"87","author":"Yoshimi","year":"2015","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.bbrc.2018.04.005_bib16","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/infdis\/jiw437","article-title":"Protease inhibitor resistance remains even after mutant strains become undetectable by deep sequencing","volume":"214","author":"Kan","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.bbrc.2018.04.005_bib17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in\u00a0vitro and in\u00a0vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2018.04.005_bib18","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in\u00a0vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2018.04.005_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29836","article-title":"NS5A-P32 deletion after failure of ledipasvir\/sofosbuvir in hepatitis C virus genotype 1b infection","author":"Doi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2018.04.005_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2018.04.005_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.29130","article-title":"Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral\u2013experienced patients with genotype 1 hepatitis C virus","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18307708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X18307708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T17:45:22Z","timestamp":1668620722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X18307708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0006291X18307708"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.04.005","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}